Most peptide interactions are unstudied. This one isn't. The growth-hormone secretagogue class raises blood sugar — it's on an approved drug's label, in randomized trials, and in an FDA risk citation. The people most exposed are the ones managing glucose without monitoring.
The exception to “nobody has studied the interactions”
Almost every page on this site has to give the same honest answer about drug interactions: unstudied. The growth-hormone secretagogue class — CJC-1295, ipamorelin, sermorelin, the GHRPs, and their close chemical cousin MK-677 — is the exception. For this class, the blood-sugar effect is not a mechanism guess. It is documented at every level of the evidence ladder.
Level one: an approved drug’s label
Tesamorelin (Egrifta) is the FDA-approved GHRH analog — same pharmacological family as the gray-market secretagogues. Its label carries a warning for glucose intolerance and diabetes risk. When the class effect is printed on the approved member’s label, treating it as a documented class concern for the unapproved members is not speculation; it is the conservative reading.
Level two: randomized trials of MK-677
MK-677 (ibutamoren) is a small molecule, not a peptide — but it works the same ghrelin pathway, is sold through the same channels, and has something no peptide in this class has: long randomized trials.
- In older adults treated for two years, MK-677 raised fasting blood sugar and reduced insulin sensitivity (Nass et al., Annals of Internal Medicine, 2008).
- It worsened glucose tolerance in obese men (Svensson et al., 1998).
- A hip-fracture recovery trial in 123 older patients was stopped early over a congestive-heart-failure signal (Adunsky et al., 2011). FDA lists ibutamoren among compounding substances presenting significant safety risks, citing the heart-failure potential.
Level three: CJC-1295’s own development record
CJC-1295 was a real drug candidate once — ConjuChem’s Phase II trial in HIV-associated lipodystrophy. In 2006 the trial was halted after a participant died of a myocardial infarction hours after a dose. The attending physician attributed the death to undiagnosed coronary artery disease and judged it unrelated to the drug; the sponsor nonetheless terminated the entire program, and no human trial of CJC-1295 has been published since (company statement, August 8, 2006; trial NCT00267527, terminated without results). FDA’s advisory-committee materials separately cite serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory (blood-vessel-widening) reaction.
We print the attribution exactly as the record holds it: one death, judged unrelated by the treating physician, in a sick population — and a sponsor that still walked away from the molecule entirely.
The combination nobody tested
The pairing that dominates community use — CJC-1295 plus ipamorelin — has never been tested as a combination in humans. Neither has any other secretagogue combination. Both components, plus sermorelin, GHRP-2 and GHRP-6, were also among the falsified products in the Belgian lab study (Janvier et al., Talanta, 2018): purity as low as 5–75% for some products in the set, about 30% carrying incorrect amino-acid sequences. So the community standard is an untested combination, of individually glucose-active compounds, sourced from a supply chain with a documented identity problem.
Who this actually endangers
Put the documented facts in one line: a class of compounds that raises blood sugar, used without glucose monitoring, by a population that includes people managing diabetes and prediabetes. A person adjusting insulin or a GLP-1 while secretly adding a secretagogue is running two unmonitored experiments on the same variable — and their clinician, who doesn’t know about the second one, will read the results as their disease changing. The interaction with diabetes medication has never been tested. The population most likely to be harmed by the documented glucose effect is the population positioned to receive it silently.
Clinician creators apply the same caution inside their own practices: Dr. Froese attributes documented insulin resistance to tesamorelin specifically, and states a practice rule of avoiding GH-axis peptides in patients with any cancer history — the class’s second standing theoretical concern, since years of elevated GH/IGF-1 signaling is the acromegaly risk pattern (see Cancer and Peptides).
Get medical care now if
- Unusual blood-sugar swings — shakiness, sweating, confusion, extreme thirst or urination — while using any secretagogue, especially if you take diabetes medication. Tell the clinician about the secretagogue; it changes what the numbers mean.
- Chest pain, fainting, or a racing heartbeat after an injection.
- New swelling of the hands or feet, or persistent numbness and tingling in the hands — report GH-axis use when you report the symptom.
If you were harmed, report it to FDA MedWatch.
The bottom line
This page exists to prove a standard: when the evidence is documented, we say documented, with the label, the trials, and the dates attached — so that when we say “unknown” on the next page, it means something. The GH / Classic stack and Muscle stack pages carry this warning in their safety boxes.
Educational information only — not medical or legal advice. Status as of November 9, 2026. See Our Legal Mandate.